Calcitonin oral - Enteris BioPharma/Tarsa Therapeutics

Drug Profile

Calcitonin oral - Enteris BioPharma/Tarsa Therapeutics

Alternative Names: Calcitonin-salmon [rDNA origin] delayed release tablets; Oral recombinant salmon calcitonin - Tarsa Therapeutics; Ostora; rsCT; Salmon calcitonin oral - Tarsa Therapeutics; sCT oral; TBRIA

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unigene Laboratories
  • Developer Enteris BioPharma; Tarsa Therapeutics
  • Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
  • Mechanism of Action Calcitonin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Postmenopausal osteoporosis
  • No development reported Osteoarthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Osteoarthritis(Combination therapy) in USA (PO)
  • 19 Oct 2015 Planned Prescription Drug User Fee Act (PDUFA) date for Postmenopausal osteoporosis in USA (PO) is 2016-05-30
  • 19 Oct 2015 The US FDA accepts NDA for oral calcitonin for Postmenopausal osteoporosis for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top